Stockscreener 앱 받기
255.77
0.05%
0.13
전일 마감가:
$255.64
열려 있는:
$262.54
하루 거래량:
180.35K
Relative Volume:
0.37
시가총액:
$26.40B
수익:
$3.81B
순이익/손실:
$-644.79M
주가수익비율:
-40.99
EPS:
-6.24
순현금흐름:
$-669.77M
1주 성능:
+4.44%
1개월 성능:
-6.92%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$254.37
$262.76
1주일 범위
$246.04
$267.00
52주 변동 폭
$172.67
$287.88
Beigene Ltd Adr Stock (ONC) Company Profile
명칭
Beigene Ltd Adr
전화
13459494123
주소
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
ONC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-07 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-03 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-12-03 | 재개 | Morgan Stanley | Overweight |
| 2024-09-18 | 개시 | JMP Securities | Mkt Outperform |
| 2024-02-06 | 재개 | JP Morgan | Overweight |
| 2023-09-12 | 개시 | Macquarie | Outperform |
| 2023-08-17 | 개시 | Jefferies | Buy |
| 2023-07-17 | 개시 | Citigroup | Buy |
| 2023-06-30 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | 개시 | Daiwa Securities | Buy |
| 2022-10-13 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-10-13 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | 재개 | JP Morgan | Overweight |
| 2022-03-17 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | 개시 | Deutsche Bank | Buy |
| 2021-10-12 | 개시 | Bernstein | Outperform |
| 2021-10-06 | 업그레이드 | CLSA | Underperform → Buy |
| 2021-03-08 | 개시 | China Renaissance | Buy |
| 2021-03-01 | 다운그레이드 | CLSA | Outperform → Underperform |
| 2020-11-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-11-06 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
모두보기
Beigene Ltd Adr 주식(ONC)의 최신 뉴스
BeiGene wins patent challenge against Pharmacyclics By Investing.com - Investing.com India
BeiGene wins US patent dispute over cancer drug - Investing.com
BeiGene reports financial results under PRC GAAP By Investing.com - Investing.com South Africa
BeiGene reports financial results under PRC GAAP - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now? - Yahoo Finance
Why Summit Therapeutics Rocketed Double-Digits Today - The Motley Fool
BigBear.ai Holdings Inc (BBAI) gets rating Downgrade from Northland Capital - knoxdaily.com
Morgan Stanley analysts upgrades an Equal-weight rating for Urban Edge Properties (UE) - knoxdaily.com
RBC Capital Mkts initates BeiGene Ltd. ADR (ONC) rating to an Outperform - knoxdaily.com
BGNE Page Not Found - Benzinga
Beigene’s Wang Xiaodong sells $10.1m in stock By Investing.com - Investing.com India
Beigene’s Wang Xiaodong sells $10.1m in stock - Investing.com
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? - Yahoo Finance
Permian Resources Corp [PR] Director makes an insider purchase of 250,000 shares worth 3.02 million. - knoxdaily.com
RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa
RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com
JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India
Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com
Beigene’s president Wu Xiaobin sells $14.6 million in shares By Investing.com - Investing.com India
Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com
Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa
Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India
Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com
Bernstein raises BeiGene stock price target to $259 - Investing.com
BeiGene CEO John Oyler sells $10 million in shares - Investing.com India
Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India
BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise
Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells $10.39 million in shares - Investing.com
BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa
Beigene SVP sells $331,375 in American depositary shares - Investing.com India
JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa
BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India
BofA lifts BeiGene stock rating, raises target to $320 By Investing.com - Investing.com South Africa
Beigene directors Julian and Felix Baker sell $190m in shares - Investing.com India
BeiGene gets FDA Orphan Drug Designation for sonrotocla - Investing.com
Guggenheim lifts BeiGene stock target to $348, maintains Buy rating - Investing.com India
Citizens JMP lifts BeiGene stock target to $348 on strong sales By Investing.com - Investing.com South Africa
Citizens JMP lifts BeiGene stock target to $348 on strong sales - Investing.com India
AASTOCKS Financial NewsBeiGene, Ltd. (ONC) - AASTOCKS.com
Beigene Ltd Adr (ONC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Beigene Ltd Adr 주식 (ONC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wang Xiaodong | Chair, Scientific Advisory Brd |
Apr 14 '25 |
Sale |
242.66 |
41,760 |
10,133,595 |
0 |
2.45%
자본화:
|
볼륨(24시간):